Full-Time

Global HR Advisor

Posted on 4/19/2025

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops tubeless insulin delivery systems

Compensation Overview

$64.7k - $97k/yr

Mid, Senior

Acton, MA, USA

This role requires onsite presence in Acton, MA 3x/week.

Category
Human Resources
People & HR
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Insulet Corporation referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree
  • Minimum of 3-5 years of experience in HR roles, with exposure to data management, communication, and reporting
  • Strong analytical skills and proficiency in HR systems; Workday experience preferred
  • Excellent written and verbal communication
  • Ability to collaborate effectively with cross-functional teams
Responsibilities
  • Distributing and collecting essential talent, performance, and compensation data to support HRBPs on midyear and key annual cycle activities, as well as special projects
  • Cross-referencing and reconciling business-specific HR data to respond to inquiries
  • Assisting HRBPs with drafting communications to managers and employees on various matters, including recognition HR practices, follow-ups, resources, and reminders
  • Guiding HRBPs and managers on transfers and internal movements
  • Managing positions and collaborating with Compensation and Talent Acquisition (TA) on leveling and salary ranges for new roles
  • Generating reports and insights for HRBPs on topics such as promotions, annual and mid-year performance reviews, headcount, turnover, open requisitions, and L&D program progress
  • Supporting HRBPs with creating presentations for Town Halls, leadership team updates, and manager forums
  • Ensuring accuracy in organizational charts and position management data within Workday
  • Providing compensation details per HRBP guidance to Talent Acquisition for offers
  • Supporting immigration or relocation requests between managers, HRBPs, and Immigration
  • Supporting HRBPs with engagement survey reports and insights and implementing next steps, including follow ups communications and organizing focus groups
Desired Qualifications
  • Workday experience preferred

Insulet Corporation develops medical devices aimed at simplifying life for people with diabetes. Their main product, the Omnipod Insulin Management System, is a tubeless device that delivers insulin continuously for up to three days without needles. The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor, allowing users to manage blood sugar without multiple injections or fingersticks. Insulet differentiates itself by providing a user-friendly solution that enhances insulin management, with the goal of improving the quality of life for individuals with diabetes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for advanced diabetes solutions expands Insulet's market opportunities.
  • Omnipod 5's European expansion increases Insulet's international market presence.
  • Advancements in sensor technology enhance the reliability of Insulet's Omnipod system.

What critics are saying

  • Leadership transition to Ashley McEvoy may lead to strategic instability.
  • Increased competition from DexCom and Tandem Diabetes Care challenges Insulet's market share.
  • Potential financial strain from $450M senior notes offering could impact cash flow.

What makes Insulet Corporation unique

  • Insulet's Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • The RADIANT trial showcases Insulet's innovation in transitioning from daily injections to Omnipod.
  • Insulet's $452M trade secret victory strengthens its competitive position in insulin pump technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
RTTNews
Apr 28th, 2025
Insulet CEO Jim Hollingshead Resigns, Ashley McEvoy To Succeed; Raises Q1 Guidance

Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.

MD+DI
Apr 28th, 2025
Insulet Names Ex-J&J MedTech Chief Ashley McEvoy as CEO

Ashley McEvoy has been tapped to be president and CEO of Insulet.

Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.

INACTIVE